Literature DB >> 22369943

Characterization of cancer stem cell properties of CD24 and CD26-positive human malignant mesothelioma cells.

Hiroto Yamazaki1, Motohiko Naito, Farhana Ishrat Ghani, Nam H Dang, Satoshi Iwata, Chikao Morimoto.   

Abstract

Malignant mesothelioma (MM) is an asbestos-related malignancy characterized by rapid growth and poor prognosis. In our previous study, we have demonstrated that several cancer stem cell (CSC) markers correlated with CSC properties in MM cells. Among these markers, we focused on two: CD24, the common CSC marker, and CD26, the additional CSC marker. We further analyzed the CSC properties of CD24 and CD26-positve MM cells. We established RNAi-knockdown cells and found that these markers were significantly correlated with chemoresistance, proliferation, and invasion potentials in vitro. Interestingly, while Meso-1 cells expressed both CD24 and CD26, the presence of each of these two markers was correlated with different CSC property. In addition, downstream signaling of these markers was explored by microarray analysis, which revealed that their expressions were correlated with several cancer-related genes. Furthermore, phosphorylation of ERK by EGF stimulation was significantly affected by the expression of CD26, but not CD24. These results suggest that CD24 and CD26 differentially regulate the CSC potentials of MM and could be promising targets for CSC-oriented therapy. Copyright Â
© 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22369943     DOI: 10.1016/j.bbrc.2012.02.054

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  15 in total

1.  Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship.

Authors:  Irina M Shapiro; Vihren N Kolev; Christian M Vidal; Yuwaraj Kadariya; Jennifer E Ring; Quentin Wright; David T Weaver; Craig Menges; Mahesh Padval; Andrea I McClatchey; Qunli Xu; Joseph R Testa; Jonathan A Pachter
Journal:  Sci Transl Med       Date:  2014-05-21       Impact factor: 17.956

Review 2.  DPPIV/CD26: a tumor suppressor or a marker of malignancy?

Authors:  Aline Beckenkamp; Samuel Davies; Júlia Biz Willig; Andréia Buffon
Journal:  Tumour Biol       Date:  2016-03-04

3.  Suppression of CD26 inhibits growth and metastasis of pancreatic cancer.

Authors:  Chunxiang Ye; Xiuyun Tian; Guanjun Yue; Liang Yan; Xiaoya Guan; Shan Wang; Chunyi Hao
Journal:  Tumour Biol       Date:  2016-10-07

4.  A Subset of Malignant Mesothelioma Tumors Retain Osteogenic Potential.

Authors:  S M Lansley; B Pedersen; C Robinson; R G Searles; G Sterrett; I van Bruggen; R A Lake; S E Mutsaers; C M Prêle
Journal:  Sci Rep       Date:  2016-11-25       Impact factor: 4.379

5.  First-in-human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expressing cancers.

Authors:  Eric Angevin; Nicolas Isambert; Véronique Trillet-Lenoir; Benoit You; Jérôme Alexandre; Gérard Zalcman; Philippe Vielh; Françoise Farace; Fanny Valleix; Thomas Podoll; Yu Kuramochi; Itaru Miyashita; Osamu Hosono; Nam H Dang; Kei Ohnuma; Taketo Yamada; Yutaro Kaneko; Chikao Morimoto
Journal:  Br J Cancer       Date:  2017-03-14       Impact factor: 7.640

6.  The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells.

Authors:  Alessandra Pattarozzi; Elisa Carra; Roberto E Favoni; Roberto Würth; Daniela Marubbi; Rosa Angela Filiberti; Luciano Mutti; Tullio Florio; Federica Barbieri; Antonio Daga
Journal:  Stem Cell Res Ther       Date:  2017-05-25       Impact factor: 6.832

7.  Multipotent cancer stem cells derived from human malignant peritoneal mesothelioma promote tumorigenesis.

Authors:  Sheelu Varghese; Rebecca Whipple; Stuart S Martin; H Richard Alexander
Journal:  PLoS One       Date:  2012-12-28       Impact factor: 3.240

8.  Type 1 Diabetes Prevention in NOD Mice by Targeting DPPIV/CD26 Is Associated with Changes in CD8⁺T Effector Memory Subset.

Authors:  Núria Alonso; María Teresa Julián; Jorge Carrascal; Roger Colobran; Irma Pujol-Autonell; Silvia Rodriguez-Fernández; Aina Teniente; Marco Antonio Fernández; Antoni Miñarro; María Carmen Ruiz de Villa; Marta Vives-Pi; Manel Puig-Domingo
Journal:  PLoS One       Date:  2015-11-10       Impact factor: 3.240

9.  CD9 negatively regulates CD26 expression and inhibits CD26-mediated enhancement of invasive potential of malignant mesothelioma cells.

Authors:  Toshihiro Okamoto; Satoshi Iwata; Hiroto Yamazaki; Ryo Hatano; Eriko Komiya; Nam H Dang; Kei Ohnuma; Chikao Morimoto
Journal:  PLoS One       Date:  2014-01-23       Impact factor: 3.240

10.  Regulation of somatostatin receptor 4-mediated cytostatic effects by CD26 in malignant pleural mesothelioma.

Authors:  J Yamamoto; K Ohnuma; R Hatano; T Okamoto; E Komiya; H Yamazaki; S Iwata; N H Dang; K Aoe; T Kishimoto; T Yamada; C Morimoto
Journal:  Br J Cancer       Date:  2014-04-17       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.